Technology
Health
Pharmaceutical

Eisai

$80.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.45 (-0.55%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Eisai and other stocks, options, ETFs, and crypto commission-free!

About

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. Read More The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan. ESALY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
10,456
Headquarters
Tokyo, Tokyo
Founded
1936
Market Cap
23.31B
Price-Earnings Ratio
40.00
Dividend Yield
1.94
Average Volume
5.02K
High Today
$81.39
Low Today
$79.59
Open Price
$81.39
Volume
1.50K
52 Week High
$101.80
52 Week Low
$62.54

Collections

Technology
Health
Pharmaceutical
Healthcare
Food
Chemicals
Asia (Non-China)
Asia

News

Yahoo FinanceMar 15

Why Eisai (ESALY) Could Be an Impressive Growth Stock

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well.

11
Seeking AlphaMar 11

Eisai Co., Ltd. ADR (ESALF) Information Meeting 2019 Conference Call (Transcript)

Eisai Co., Ltd. ADR (OTCPK:ESALF) Information Meeting 2019 Conference Call March 8, 2019 2:00 AM ET Company Participants Haruo Naito - Representative Corporate Officer and CEO Hiroyuki Kobayashi - Medical Division Ryohei Yanagi - CFO Ivan Cheung - SVP, President of Neurology Business Group Dr. Takashi Owa - VP and Chief Medicine Creation Officer & Chief Discovery Officer of Oncology Business Masanori Tsuno - Deputy Chief Clinical Officer of Neurology Business Teiji Kimura - Vice President, Chief Dis...

8
Seeking AlphaMar 11

FDA to review Eisai and Imbrium Therapeutics' NDA for lemborexant

The FDA has accepted for review Eisai (OTCPK:ESALY) and Imbrium Therapeutics' New Drug Application (NDA) for lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder.

8
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.